Employee warrant exercise adds new shares at Genmab (Nasdaq: GMAB)
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Positive
- None.
Negative
- None.
Key Figures
New shares issued: 2,346 shares
Proceeds: DKK 3.0 million
Dilution: 0.004%
+4 more
7 metrics
New shares issued
2,346 shares
Employee warrant exercise
Proceeds
DKK 3.0 million
Cash from warrant exercises
Dilution
0.004%
Portion of Genmab’s share capital
Subscription price batch 1
DKK 1,147.50/share
908 shares
Subscription price batch 2
DKK 1,334.50/share
759 shares
Subscription price batch 3
DKK 1,362.50/share
679 shares
Total share capital after increase
62,353,067 shares
Nominal DKK 62,353,067
Key Terms
employee warrants, preemption rights, share capital, Danish Capital Markets Act, +1 more
5 terms
employee warrants financial
"Genmab A/S will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants."
preemption rights financial
"The increase is effected without any preemption rights for the existing shareholders of the Company or others."
Preemption rights give existing shareholders the first chance to buy newly issued shares so they can keep the same fraction of ownership. Think of it like getting first dibs on extra slices of pizza so your portion of the pie doesn’t shrink. For investors this matters because it protects voting power and value per share by preventing unexpected loss of ownership when a company issues more stock.
Danish Capital Markets Act regulatory
"Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced"
A national law that sets the rules for trading, reporting and oversight of securities and financial markets in Denmark; think of it as the official rulebook that governs how companies, investors and intermediaries must behave when raising capital or trading shares. It matters to investors because it mandates information disclosure, market transparency and conduct standards that reduce fraud, make prices more reliable and protect shareholder rights, helping investors judge risks and make informed decisions.
forward looking statements regulatory
"The Company Announcement contains forward looking statements."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated May 12, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: May 12, 2026
Exhibit 99.1
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
908 shares at DKK 1,147.50,
759 shares at DKK 1,334.50, and
679 shares at DKK 1,362.50.
Proceeds to the Company are approximately DKK 3.0 million. The increase corresponds to approximately 0.004% of the Company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,353,067 which is made up of 62,353,067 shares of a nominal value of DKK 1 each, corresponding to 62,353,067 votes.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 27 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Capital Increase in Genmab as a Result of Employee Warrant Exercise
relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 27 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What capital increase did Genmab (GMAB) announce in May 2026?
Genmab announced a small capital increase of 2,346 shares from employee warrant exercises, equal to about 0.004% of its share capital, reinforcing its equity base with new cash proceeds.
How much cash does Genmab (GMAB) receive from the warrant exercise?
Genmab receives approximately DKK 3.0 million from the employee warrant exercise, providing additional cash to the company as the new shares are fully paid in cash at specified subscription prices.